SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cell Death and Differentiation

• Publication date

  2011-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/cdd.2011.71PMID 21637290PMCID PMC3170683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

  2011cited by this paper
• The role of mutant p53 in human cancer

  2011cited by this paper
• Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes

  2011cited by this paper
• Induction of TAp63 by histone deacetylase inhibitors.

  2010cited by this paper
• A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.

  2009cited by this paper
• Mutant p53 drives invasion by promoting integrin recycling.

  2009cited by this paper
• Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.

  2009cited by this paper
• Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6

  2009cited by this paper
• Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.

  2008cited by this paper
• The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

  2008cited by this paper
• Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.

  2008cited by this paper
• Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis

  2007cited by this paper
• Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.

  2007cited by this paper
• Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

  2007cited by this paper
• An acetylation site in the middle domain of Hsp90 regulates chaperone function.

  2007cited by this paper
• Ubiquitination and Degradation of Mutant p53

  2007cited by this paper
• Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

  2006cited by this paper
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

  2006cited by this paper
• Anticancer activities of histone deacetylase inhibitors

  2006cited by this paper
• ICI182,780 Induces p21Waf1 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor α from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line*

  2005cited by this paper
• Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.

  2005cited by this paper
• HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• The Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation*

  2005cited by this paper
• Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3

  2004cited by this paper
• Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

  2004cited by this paper
• Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.

  2004cited by this paper
• Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

  2004cited by this paper
• Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

  2003cited by this paper
• Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.

  2003cited by this paper
• Chemosensitivity linked to p73 function.

  2003cited by this paper
• Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

  2002cited by this paper
• Co‐chaperones Bag‐1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild‐type or mutant p53

  2001cited by this paper
• Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

  1999cited by this paper
• The Physical Association of Multiple Molecular Chaperone Proteins with Mutant p53 Is Altered by Geldanamycin, an hsp90-Binding Agent

  1998cited by this paper
• Mutant p53 protein expression interferes with p53-independent apoptotic pathways

  1998cited by this paper
• Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo

  1997cited by this paper

• The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications.

  2026cites this paper
• TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approaches

  2026cites this paper
• The dual face of reprogrammed proteostasis in cancer and its epigenetic regulation: A survival option and a therapeutic opportunity.

  2026cites this paper
• Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction

  2025cites this paper
• Valemetostat–SAHA-Driven Acetylation of p53 via SET/TAF-Iβ Displacement and p300 Activation Modulates Cell Cycle Regulators in Pancreatic Cancer Cells

  2025cites this paper
• p53 in colorectal cancer: from a master player to a privileged therapy target

  2025cites this paper
• Mutant p53 upregulates HDAC6 to resist ER stress and facilitates Ku70 deacetylation, which prevents its degradation and mitigates DNA damage in colon cancer cells

  2025cites this paper
• Gambogic acid restores wild-type-like p53 functions to induce ferroptosis in mutant p53 cancer cells

  2025cites this paper
• Acetylation promotes mutant (MUT) TP53-HSPA8 and HSPA8-BAG3 interactions, facilitating MUT TP53 lysosomal degradation preferentially via CASA

  2025influential citation
• The key vulnerabilities and therapeutic opportunities in the USP7-p53/MDM2 axis in cancer.

  2025cites this paper
• GANNET53 Part II: A European Phase I/II Trial of the HSP90 inhibitor Ganetespib in high-grade Platinum-Resistant Ovarian Cancer - A Study of the GANNET53 consortium.

  2025cites this paper
• Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers

  2025cites this paper
• Glucose metabolic dysregulation and oxidative stress in cholangiocarcinoma: molecular mechanisms, oncogenic drivers, and novel therapeutic targets

  2025cites this paper
• Vitamin D and SIRT1 activator SRT2104 cooperate in antiproliferative activity in lung cancer through ferroptosis induction.

  2025cites this paper
• The Role of p53 as the Guardian of the Genome and the Consequences of its Mutation in Cancer Development: A Review

  2025cites this paper
• Lactylation-driven transcriptional activation of FBXO33 promotes gallbladder cancer metastasis by regulating p53 polyubiquitination

  2025cites this paper
• Zinc Finger Protein 82 regulates p53 protein stability through histone deacetylase and enhances neo-adjuvant chemotherapy in esophageal cancer

  2025cites this paper
• Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth

  2025cites this paper
• The Multifaceted Role of p53 in Cancer Molecular Biology: Insights for Precision Diagnosis and Therapeutic Breakthroughs

  2025cites this paper
• TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds

  2025cites this paper
• SAHA/5-AZA Enhances Acetylation and Degradation of mutp53, Upregulates p21 and Downregulates c-Myc and BRCA-1 in Pancreatic Cancer Cells

  2024cites this paper
• Dominant-negative TP53 mutations potentiated by the HSF1-regulated proteostasis network

  2024influential citation
• Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions

  2024cites this paper
• From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

  2024cites this paper
• Translating p53-based therapies for cancer into the clinic

  2024cites this paper
• Elucidating the immune landscape and potential prognostic model in acute myeloid leukemia with TP53 mutation

  2024cites this paper
• Post-Translational Modifications (PTMs) of mutp53 and Epigenetic Changes Induced by mutp53

  2024cites this paper
• Synthesis and characterization of 64Cu-labeled Geldanamycin derivative for imaging HSP90 expression in breast cancer.

  2024cites this paper
• Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53

  2024cites this paper
• Unraveling the Guardian: p53’s Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies

  2024cites this paper
• The Multiple Roles of Heat Shock Proteins in the Development of Inflammatory Bowel Disease.

  2024cites this paper
• Corrigendum to Targeting apoptotic pathways for cancer therapy

  2024cites this paper
• Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant.

  2024cites this paper
• TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)

  2024cites this paper
• Augmented Global Protein Acetylation Diminishes Cell Growth and Migration of Cholangiocarcinoma Cells

  2024cites this paper
• Targeting mutant p53: a key player in breast cancer pathogenesis and beyond

  2024cites this paper
• Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer—The Possibility or the Necessity?

  2023cites this paper
• “DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies

  2023cites this paper
• Acetylation halts missense mutant p53 aggregation and rescues tumor suppression in non-small cell lung cancers

  2023cites this paper
• STUB1/CHIP: New insights in cancer and immunity.

  2023cites this paper
• Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53.

  2023cites this paper
• New molecular targets in canine hemangiosarcoma-Comparative review and future of the precision medicine.

  2023cites this paper
• P53 together with ferroptosis: a promising strategy leaving cancer cells without escape

  2023cites this paper
• Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials

  2023cites this paper
• Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas

  2023cites this paper
• Targeting mutant p53 stabilization for cancer therapy

  2023cites this paper
• TP53 signal pathway confers potential therapy target in acute myeloid leukemia

  2023influential citation
• Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer

  2023cites this paper
• Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles

  2023cites this paper
• Enhanced Cytotoxic Effects in Human Oral Squamous Cell Carcinoma Cells Treated with Combined Methyltransferase Inhibitors and Histone Deacetylase Inhibitors

  2022cites this paper
• Should mutant TP53 be targeted for cancer therapy?

  2022cites this paper
• The chaperone system in glioblastoma multiforme and derived cell lines: diagnostic and mechanistic implications.

  2022cites this paper
• Synthesis, in vitro and structural aspects of cap substituted Suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in Glioblastoma cancer cells via HDAC /microRNA regulation.

  2022cites this paper
• Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations.

  2022cites this paper
• Iron increases the susceptibility of colorectal cancer cells to compound Kushen Injection via the decrease of TOP2A and p53

  2022cites this paper
• Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.

  2022cites this paper
• Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells

  2022cites this paper
• VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor

  2022cites this paper
• A common pathway to cancer: Oncogenic mutations abolish p53 oscillations.

  2022cites this paper
• It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy

  2022cites this paper
• Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis

  2022cites this paper
• Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

  2022cites this paper
• Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches

  2022cites this paper
• Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer

  2022cites this paper
• Identification of 3-Phenylquinoline Derivative PQ1 as an Antagonist of p53 Transcriptional Activity

  2022cites this paper
• Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression

  2022cites this paper
• HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53

  2022cites this paper
• GOF Mutant p53 in Cancers: A Therapeutic Challenge

  2022cites this paper
• Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53

  2022cites this paper
• Emerging Link between Tsc1 and FNIP Co-Chaperones of Hsp90 and Cancer

  2022cites this paper
• Colletofragarone A2 Inhibits Cancer Cell Growth In Vivo and Leads to the Degradation and Aggregation of Mutant p53.

  2022cites this paper
• Nondiploid cancer cells: Stress, tolerance and therapeutic inspirations.

  2022cites this paper
• Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma

  2022cites this paper
• Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.

  2021cites this paper
• The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy

  2021cites this paper
• The Role of p53 Signaling in Colorectal Cancer

  2021cites this paper
• Regulation of p53 by E3s

  2021cites this paper
• Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.

  2021cites this paper
• The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model

  2021cites this paper
• FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11

  2021cites this paper
• Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.

  2021cites this paper
• Synthesis and biological evaluation of a novel anticancer agent CBISC that induces DNA damage response and diminishes levels of mutant-p53.

  2021cites this paper
• Colletofragarone A2 and Colletoins A-C from a Fungus Colletotrichum sp. Decrease Mutant p53 Levels in Cells.

  2021cites this paper
• Targeting mutant p53 for cancer therapy: direct and indirect strategies

  2021cites this paper
• A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications.

  2021cites this paper
• Cancer Stemness: p53 at the Wheel

  2021cites this paper
• Amplifying Tumor–Stroma Communication: An Emerging Oncogenic Function of Mutant p53

  2021cites this paper
• Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells

  2021cites this paper
• TP53 in Myelodysplastic Syndromes

  2021cites this paper
• Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

  2021cites this paper
• Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90

  2021cites this paper
• Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes

  2021cites this paper
• Mutant p53 as a Regulator and Target of Autophagy

  2021cites this paper
• TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

  2021cites this paper
• Oncogenic alterations in the p53 pathway abolish oscillatory competence

  2021cites this paper
• Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma

  2021cites this paper
• D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy

  2021cites this paper
• Hyaluronic Acid-Functionalized Nanomicelles Enhance SAHA Efficacy in 3D Endometrial Cancer Models

  2021cites this paper
• Structural and Drug Targeting Insights on Mutant p53

  2021cites this paper
• Noncanonical roles of p53 in cancer stemness and their implications in sarcomas.

  2021cites this paper